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SUMMARY 
The gene of the major membrane antigen (gp250/350) of the Epstein-Barr virus (EBV) was isolated and 
inserted under the control of the SV40 early promoter into a eukaryotic expression vector, which allows 
selection for dhfr’ phenotype. Following transfection with this vector, Chinese hamster ovary cells express 
on their surfaces proteins immunologically similar to the major EBV membrane antigen. The transcript 
encoding p250/350 is processed by partial splicing similarly but more efficiently than in B95-8 cells from which 
the DNA originates. 
INTRODUCTION 
EBV can cause infectious mononucleosis after 
primary infection and can consequently be detected 
lifelong in B-lymphocytes. The virus is believed to be 
an etiological factor in the development of Burkitt’s 
* To whom correspondence and reprint requests should be 
addressed. 
Abbreviations: bp, base pair(s); CHO, Chinese hamster ovary; 
DHFR, diiydrofolate reductase; dhfr, diydrofolate reductase 
gene; gp, glycoprotein; Ig, immunoglobulin; kb, kilobase or 
1000 bp; MA, membrane antigen; mcs, multiple cloning site; 
NPC, nasopharyngeal carcinoma; nt, nucleotide(s); ORF, open 
reading frame; PAGE, polyacrylamide gel electrophoresis; SDS, 
sodium dodecyl sulfate; SSC, 0.15 M NaCl, 0.015 M Na, . citrate, 
pH 7.6; SV40, simian virus 40. 
lymphoma and is to 100% associated with the 
undifferentiated form of NPC, which is one of the 
most common tumors amongst he Southern Chi- 
nese population (for review, see Epstein and 
Achong, 1979). The prevention or delay of EBV 
infection through vaccination would reduce the risk 
of developing NPC and EBV-related lymphomas 
and would be of substantial benefit (Epstein, 1976). 
Large-scale preparation of virus for a vaccine, based 
on inactivated viral particles or fractions derived 
from it, would not be feasible due to the low, 
inefftcient replication rate of the virus in cell culture. 
A second reason to circumvent his type of vaccine 
production from whole virus is the potential trans- 
forming activity of the viral genome, which would 
require preparations essentially free of viral trans- 
forming genes. 
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Fig. 1. Construction scheme of the eukaryotic expression vector pMDIIIGP carrying the dhfr gene and gp250/350_encoding gene with 
transcriptional regulation sequences. At the top a part of the leftward strand of the BumHI-L of the EBV B95-8 strain is shown. The 
open bar represents the coding region for the gp250/350 (ORF BLLFl, Baer et al., 1984) with restriction enzyme sites (abbreviations 
see below) used for engineering in pUC plasmid vectors (Yanisch-Perron et al., 1985). The fragment spliced out from the mRNA to yield 
gp250 is indicated by “splice” and lines. The lines below represent sequences which were subcloned as indicated. The 230-bp fragment 
Investigation of the composition of the viral 
membrane proteins have identified at least two gly- 
coproteins of M,s 250000 and 350000 (gp250/350) 
which have common antigenic determinants 
(Quahiere and Pearson, 1979; 1980; Thorley- 
Lawson and Edson, 1979). The reading frame en- 
coding both proteins is found within the BumHI-L 
fragment of EBV. The differences in M, are caused 
by an incomplete splice event which removes an 
internal part from the mRNA encoding gp350 to 
yield a smaller message ncoding gp250 in the same 
frame as gp350 (Beisel et al., 1985). Epstein et al 
(1985) showed that an immunization of cotton top 
tamarins with the purified gp350 from EBV-produc- 
ing cells protects animals from a lethal challenge of 
EBV. They advocate the use of this protein as a 
subunit vaccine. Recently, Mackett and Arrand 
(1985) showed the expression of gp350 in eukaryotic 
cells infected by recombinant vaccinia virus. We 
report here the expression in an eukaryotic system 
which produces both proteins with their glycosy- 
lations. As host cells we used CHO cells deficient of 
the dhfr gene and an expression vector carrying this 
gene and the gp250/350-encoding sequences under 
the control of the SV40 early gene promoter. 
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EXPERIMENTAL AND DISCUSSION 
(a) Cloning of the glycoprotein encoding sequence 
and construction of the expression vector 
pMDIIIGP. 
The eukaryotic expression vector was constructed 
in Escherichiu coli from three parental plasmids. As 
backbone, the plasmid pSVE (Breathnach and 
Harris, 1983) was used. It contains the bacterial 
sequences necessary for maintenance in E. coli (orig- 
in of replication and /3-lactamase gene), an SV40 
early promoter and the rabbit globin splice donor 
and acceptor sites. The dhfr together with SV40 
enhancer sequences, the adeno major late promoter, 
a splice acceptor site and the SV40 early polyadeny- 
lation site originate from pAdD26SV(A) (Kaufman 
and Sharp, 1982). The third parental plasmid 
contains the gp250/350 encoding BarnHI-L frag- 
ment of the EBV genome from the producing 
lymphoid cell line B95-8 (Skare and Strominger, 
1980). 
At the top of Fig. 1 the coding region for 
gp250/350 with restriction enzymes used for sub- 
cloning is shown. We engineered the gp250/350 gene 
such that its translational initiation codon is located 
at the end of a fragment which could be excised from 
the pUC plasmid vector by digestion with BumHI, 
XbaI or SalI. The strategy to obtain this plasmid, 
pUC18GP, is graphically indicated in Fig. 1. Ac- 
cording to the sequence, the blunt end ligation of the 
derived from MnlI digestion was inserted into pUCl2 linearized with HincII. The resulting plasmid, pUCLM1, carries the translational 
start of the gp gene plus three additional bp as it was found by DNA sequence analysis (not shown). A lOO-bp EcoRI-BarnHI fragment 
was isolated from it and inserted into pUC8 (pUCLEl00). From BumHI-L the 635bp EcoRI fragment was inserted into this clone to 
obtain pUCLE700. A 2614-bpHindIII-HincII fragment including the translational stop and the polyadenylation site (arrow) was isolated 
from BarnHI-L and inserted into pUCl8 (pUCLH2.6). The 5’ part of the gene was excised as 365-bp Hind111 fragment from pUCLE700 
and combined with pUCLH2.6 to obtain the construct pUCl8GP. From this clone the gp250/350 coding sequence can be excised with 
BumHI, XbaI or SalI. The dhfr gene was recloned from pAdD26SV(A) (Kaufman and Sharp, 1984) by insertion of a 1130-bp Hind111 
fragment into pUCl8 (pUCSV) and of a 1990-bp EcoRI-BarnHI fragment into pUC8 (pUCDH). A 260-bp EcoRI fragment of pUCSV 
was isolated and inserted into pUCDH to obtain the construct pUCSVDH, from which the dhji with its transcriptional regulation 
sequences can be isolated as a Sal1 fragment. This sequence was combined with the vector pSVE previously engineered by insertion 
of the mcs of pUC18 (pMD1). As final step the gp250/350-encoding XbuI fragment of pUCl8GP was integrated to obtain pMDIIIGP. 
Open segment, gp250/350-encoding sequence; tilled-in segment, dhfr; segment with dark dots, SV40 enhancer sequence; hatched 
segment, adeno major late promoter and splice donor site; thin open segment, splice signal sequences (upstream from the gp250/350 
gene, /l-globin splice donor and acceptor sites; Van den Berg et al., 1978, intron sequence as thin line; upstream from the dhfr, splice 
acceptor site from an antibody heavy chain variable region, Bothwell et al., 1981; segment with concentric lines, SV40 early promoter; 
open segment with diamonds, SV40 polyadenylation site; heavy line, sequences derived from the pUC-encoded mcs. Abbreviations: B, 
BumHI; E,EcoRI; H, HlndIII; Hc,HincII; Mn,MnlI; P,PsrI; S, SalI; X,XbuI. Only in pMDIIIGP the transcriptional starts ofmRNAs 
encoding gp250/350 and the DHFR are indicated as angular arrows, polyadenylation sites as arrows. Except for the coding region in 
the upper part of the figure the schemes are not drawn to scale. 
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i&WI fragment with pUC12 should regenerate the 
H&II or Sal1 site since the M&I digestion should 
leave a GAC 5’ of the transcriptional start. However, 
this site was absent and by nt sequence analysis we 
showed that during the cloning procedure one base 
(G) had been deleted from the EBV MnlI fragment. 
The sequence from the pUC12 polylinker (from 
XbaI) to the start codon of gp250/350 reads: TCT 
AGA GTC ACA ATG. Since the deletion does not 
affect the translational initiation we used this clone 
for further engineering (Fig. 1). 
The plasmid pAdD26SV(A) was reconstructed 
such that the dhfr gene with its transcriptional signals 
could be excised from the resulting plasmid, 
pUCSVDH as a cassette with Sal1 (Fig. 1). 
Between the EcoRI and Sal1 sites of pSVE we 
inserted the mcs of pUC18. This clone, pMD1, was 
used as the backbone of the expression vector. The 
dhfr sequences were integrated into the Sal1 site and 
the gp250/350 encoding fragment was inserted 3’ of 
the SV40 promoter and splice signals to yield the 
final vector, pMDIIIGP. 
(b) Transfection of CM0 cells and detection of 
gp250/350 
Cultured dhfr- CHO cells were transfected (Gra- 
ham and Van der Eb, 1973) with the plasmids 
pMDIIIGP and as control with pMDII1, which 
lacks the gp250/350 gene. After selection in medium 
B1234 cl2345 
116. 
Fig. 2. Detection ofthe gp250/350 in CHO cells transfected with pMDIIIGP and selected for dhfr + phenotype. (A) Immunofluorescence. 
Cells were initially incubated with a monoclonal antibody specific for gp250/350 (1 lD7; W.J., unpublished) and subsequently with a 
fluorescein-labeled rabbit anti-mouse IgG antibody. Examination of the cells under UV light shows a membrane fluorescence which 
indicates the expression of the gp250/350 and its localization in the cytoplasmic membrane. (B) Identification and localization. Surfaces 
of immunofluorescence-positive cells were labeled with ‘*sI (Jilg and Hannig, 1981) and solubilized with NP40. The EBV-related MA 
was immunoprecipitated with the mentioned monoclonal antibody and analysed through SDS-IO% PAGE and autoradiography (Jilg 
and Wolf, 1985). Lanes: (1) aliquot of the NP40 extract; (2) aliquot of the NP40 unsoluble pellet; (3) immunoprecipitation of proteins 
from the NP40 extract with the monoclonal antibody specific for gp250/350; (4) same as lane (3), but with a monoclonal antibody directed 
against a viral capsid component of EBV. Sizes at the left margin in kDa. (C) Reactivity with antibodies of NPC patients, Mr and ratio 
of gp250-gp350 compared with the authentic gp of B95-8. NP40 extracts of ‘*sI-labeled surface proteins were precipitated with a serum 
pool from NPC patients and analysed through SDS-7.5% PAGE and autoradiography. Lanes: (1) B95-8 cells; (2) and(3) immunofluore- 
scence-positive CHO clones; (4) CHO clone transfected with control plasmid pMDII1; (5) EBV-negative BJA cells. The recombinant 
gps have sligthly smaller M,.s than those from B95-8 cells, which mainly produce the 350-kDa component (both proteins are marked 
by a black dot). 
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lacking all nt the appearance of DHFR-positive cells 
was clearly visible after two to three weeks. The cells 
transfected with the control plasmid had a normal 
growth behavior and could be picked from the plates 
very easily, whereas the colonies derived from trans- 
fection with pMDIIIGP showed very slow growth 
and most of them died after reaching a colony size 
of about 100-200 cells. Only a few could be picked 
from the plates and grown to a larger scale. Finally, 
after several passages the cells approached normal 
division rates. Four clones derived from the trans- 
fection with pMDIIIGP were expanded and two of 
them were found to be positive in an immuno- 
fluorescence test for EBV membrane-specific 
fluorescence (Fig. 2A). The identification and locali- 
zation of the recombinant produced gp250/350 is 
shown in Fig. 2B. A CHO cell clone positive in the 
immunofluorescence was surface-labeled with ‘251. 
Through NP40 extraction only membrane proteins 
become solubilized and the appearance of two 
iodinated proteins in the expected M,.s of 250000 
and 350000 in the extract but not in the insoluble 
fraction indicates a localization in the cell membrane. 
Both proteins are recognized by the monoclonal 
antibody used for immunofluorescence but not by an 
antibody specific for a viral capsid antigen (anti- 
~150; W.J., unpublished). The reactivity of human 
sera derived from NPC patients and the size com- 
parison to the authentic proteins from the EBV 
producer cell line B95-8 are shown in Fig. 2C. The 
proteins produced by the CHO clones were recog- 
nized by the NPC sera as the authentic EBV MA, but 
have M,s significantly lower than the gp250/350 of 
B95-8 cells. This may be caused by a decrease of 
posttranslational glycosylation as compared to the 
lymphoid B95-8 cell. The ratio of the two proteins is 
nearly equal and indicates that the CHO post- 
transcriptional system recognizes the splice signals 
more efficiently than B95-8 cells, where only a minor 
fraction of the gp-encoding mRNA is processed to 
yield gp250. 
We have no exact explanation for the very low 
yield of stable MA-producing clones. It seems possi- 
ble, that especially in the selection phase, when the 
cells are in a depleted medium, the integration of the 
foreign glycoprotein into the cell membrane impedes 
the viability of these recombinants. 
kb kb 
3.2, -3.1 
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Fig. 3. Analysis of EBV-specific transcripts by Northern blotting 
of cytoplasmic RNA from two gp250/350 positive cell clones 
(carrying pMDIIIGP), from one negative clone (pMDII1) and 
from two EBV-producer cell lines (B95-8 and P3HRl). 1Opg 
RNA obtained according to Chirgwin et al. (1979) and pelleted 
through CsCl, (1.8 g/ml) was electrophoresed on a 1 y. agarose 
gel in the presence of 6% formaldehyde. After transfer to nitro- 
cellulose, EBV-specific transcripts were hybridized with 
[32P]pUC18GP in 50% formamide, 5 x SSC and 2 x Den- 
hardt’s solution at 50°C. The filter was washed 4 x 5 min with 
2 x SSC and 0.1% SDS at room temperature and 2 x 15 min 
with 0.1 x SSC and 0.1 y0 SDS at 68°C and finally exposed to 
an X-ray film for 24 h. To show the sizes of the transcripts (2.6 
and 3.2 kb) in comparison to EBV-producing cells, RNA from 
B95-8 and P3-HRl cells (2.5 kb and 3.1 kb) were also applied. 
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transcripts 
The organization of the transfected sequences was 
studied by Southern blot analysis, using pMDIIIGP 
as probe. Complex patterns were observed, suggest- 
ing that DNA rearrangement had occurred (not 
shown). A Northern blot with cytoplasmic RNA 
hybridized with labeled pUC18GP shows the EBV- 
specific transcription products (Fig. 3). The mRNAs 
of positive CHO cells have slightly larger sizes than 
the transcripts from B95-8 cells. Beisel et al, (1985) 
determined the start of the gp250/350 encoding 
mRNA to be 19 nt 5’ of the translational start codon 
in B95-8 cells. The recombinant CHO cells, however, 
have different 5’-untranslated sequences. The SV40 
promoter fragment (when the early promoter is used 
for initiation) contributes 60 nt (O’Hare et al., 1981), 
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(Van den Berg et al., 1978) and the polylinker 
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1980). 
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CHO clones with methotrexate and the purification 
of the gp250/350 are in progress. Since the glycopro- 
teins are integrated in the cell membranes an amplifi- 
cation may lead to overcrowding of the cell surface. 
Amplification may also be diflicult because of a pos- 
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quence is removed and where the expression product 
should consequently be secreted into the medium. 
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